TORONTO and CHICAGO, July 19, 2021 (Globe NEWSWIRE) — Medexus Prescription drugs Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is happy to announce the appointment of Marcel Konrad as Chief Fiscal Officer of the Firm, helpful quickly. Mr. Konrad succeeds Roland Boivin, who is stepping down soon after virtually a decade in the part. Mr. Boivin has agreed to stay on in an advisory ability in order to enable guarantee an orderly transition of responsibilities to Mr. Konrad in excess of the subsequent close to three months.
“I want to consider this prospect on behalf of all of us at Medexus to thank Roland for all of his attempts and devoted company and to would like him the extremely most effective in his long run endeavours,” explained Ken d’Entremont, the Company’s Main Govt Officer.
“I am grateful for the possibility to have labored with the total Medexus crew and to have performed a crucial position in transitioning the Organization from a smaller Canadian-only player into a North-American business leader in progressive orphan drug and unusual disease products,” mentioned Roland Boivin. “I’m self-confident that Medexus is positioned to continue on to prosper and I glance ahead to working with Mr. Konrad, Ken and the government workforce to guarantee a smooth changeover.”
Wanting ahead, Mr. Konrad delivers in excess of 20 years of encounter in accounting, finance and business enterprise across various global markets, such as the United States. Mr. Konrad joins the Firm from CareDx, Inc. (Nasdaq: CDNA), a precision drugs solutions corporation, the place he has served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller since 2018, such as a stint as acting Main Monetary Officer in early 2021. Even though at CareDx, Inc., Mr. Konrad was tasked with scaling multinational accounting, finance and small business operations like streamlining processes and techniques when navigating the integration of several financings and cross-border acquisitions.
Prior to becoming a member of CareDx, Inc., Mr. Konrad worked in related roles at Santen Inc., a US subsidiary of a publicly stated Japanese pharmaceutical enterprise with worldwide operations, and held numerous roles at Novartis Prescription drugs, the two in the US and Switzerland. Mr. Konrad retains an International MBA from the University of San Diego and graduated Organization Administration from HEC Lausanne, University of Lausanne, Switzerland. Mr. Konrad is an lively US Qualified General public Accountant and through his tenure at Novartis has done the Finance Management Program at the Harvard Small business College.
“Marcel delivers to Medexus a mixture of economical acumen, strategic and business knowledge and world-wide operational leadership encounter that will be a must have to the Enterprise. We extremely considerably appear forward to Marcel commencing his Medexus journey,” Mr. d’Entremont said.
About Medexus Prescribed drugs Inc.
Medexus is a chief in innovative scarce sickness procedure answers with a robust North American industrial system. From a foundation of verified best in class products and solutions we are creating a hugely differentiated firm with a portfolio of revolutionary and significant price orphan and rare disease items that will underpin our progress for the upcoming ten years. The Company’s vision is to present the greatest health care products to healthcare experts and clients, through our main values of Quality, Innovation, Shopper Service and Teamwork. Medexus Prescribed drugs is concentrated on the therapeutic spots of car-immune condition, hematology, and allergy. The Company’s leading products and solutions are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (car-pen and pre-crammed syringe) designed to deal with rheumatoid arthritis and other car-immune conditions IXINITY®, an intravenous recombinant variable IX therapeutic for use in individuals 12 yrs of age or older with Hemophilia B – a hereditary bleeding problem characterised by a deficiency of clotting component IX in the blood, which is necessary to regulate bleeding and Rupall®, an impressive prescription allergy treatment with a unique mode of motion.
For extra info, you should contact:
Ken d’Entremont, Main Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: [email protected]
Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
E mail: [email protected]
Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: [email protected]
